Cargando…
What makes cancer stem cell markers different?
Since the cancer stem cell concept has been widely accepted, several strategies have been proposed to attack cancer stem cells (CSC). Accordingly, stem cell markers are now preferred therapeutic targets. However, the problem of tumor specificity has not disappeared but shifted to another question: h...
Autores principales: | Karsten, Uwe, Goletz, Steffen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3710573/ https://www.ncbi.nlm.nih.gov/pubmed/23888272 http://dx.doi.org/10.1186/2193-1801-2-301 |
Ejemplares similares
-
Immunoreactivity of the fully humanized therapeutic antibody PankoMab-GEX™ is an independent prognostic marker for breast cancer patients
por: Heublein, Sabine, et al.
Publicado: (2015) -
Subversion of Niche-Signalling Pathways in Colorectal Cancer: What Makes and Breaks the Intestinal Stem Cell
por: Sphyris, Nathalie, et al.
Publicado: (2021) -
Human Cell Line-Derived Monoclonal IgA Antibodies for Cancer Immunotherapy
por: Hart, Felix, et al.
Publicado: (2017) -
And yet... what makes the difference?
por: Benea, Șerban, et al.
Publicado: (2013) -
Positive and negative AIT trials: What makes the difference?
por: Gerth van Wijk, Roy
Publicado: (2018)